<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159091</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-RN-005</org_study_id>
    <nct_id>NCT03159091</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain additional data on efficacy and safety of Rengalin in
      the treatment of cough in patients with stable obstructive pulmonary disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a positive treatment response</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
    <description>response criterion: ≥1 lower total Cough Severity scale (CSS) score compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of cough compared to baseline</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
    <description>total CSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ≥50% lesser cough severity</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
    <description>based on total CSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical symptoms of Chronic Obstructive Pulmonary Disease (COPD)</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
    <description>total COPD Assessment Test (CAT) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with no exacerbation of COPD</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of cough and other respiratory patterns compared to baseline</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
    <description>24-hr monitoring (with the WHolter™)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Rengalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rengalin</intervention_name>
    <description>Oral. Single dose: 2 tablets (to be held in the mouth until dissolution is complete).
Dosage regimen: 2 tablets three times daily, not concomitantly with food (i.e., 15-30 minute before or 15-30 minutes after eating)</description>
    <arm_group_label>Rengalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral. Single dose: 2 tablets (to be held in the mouth until dissolution is complete).
Dosage regimen: 2 tablets three times daily, not concomitantly with food (i.e., 15-30 minute before or 15-30 minutes after eating)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sexes aged from 40 to 80 years old.

          2. COPD diagnosed (in accordance with the GOLD-2014 guidelines) ≥12 months before
             inclusion.

          3. Stable course of COPD (≥ 6 weeks free of disease progression).

          4. Mild, moderate or severe degree of bronchial obstruction (FEV1/FVC &lt; 0.7;
             post-bronchodilator FEV1 ≥30% of predicted value).

          5. CSS score ≥2.

          6. Stable dose of standard therapy within the preceding 4 weeks.

          7. Use of and adherence to contraceptive methods by fertile-age patients of both sexes
             during the study.

          8. Availability of a signed patient information sheet (Informed Consent form) for
             participation in the trial.

        Exclusion Criteria:

          1. Earlier diagnosis of intra- or extrathoracic causes of cough (e.g., asthma, malignant
             neoplasm of lung, tuberculosis, sarcoidosis, α1-antitrypsin deficiency,
             bronchiectasis, cystic fibrosis, interstitial pulmonary diseases, perennial allergic
             rhinitis, gastro-oesophageal reflux disease, use of ACE inhibitors, disease of upper
             respiratory tract, etc.).

          2. Cough associated with eating.

          3. An exacerbation of COPD, acute upper and/or lower respiratory infection at inclusion
             or in the previous 4 weeks.

          4. Modifications to standard drug therapy (dose escalation, replacement of medicines
             prescribed or addition of new medications) in the previous 4 weeks.

          5. Very severe degree of bronchial obstruction (post-bronchodilator FEV1 &lt;30% pred or &lt;
             50% and chronic respiratory failure).

          6. Haemoptysis.

          7. Stroke in the preceding 3 months or stroke with long-term residual neurological
             deficit within 6 months before study entry.

          8. Acute coronary syndrome, myocardial infarction within 6 months before study
             enrollment.

          9. Unstable or life-threatening arrhythmia in the previous 3 months.

         10. Acute or chronic heart failure (NYHA (1964) Class III or IV).

         11. Presence or suspicion of oncological disease.

         12. Body Mass Index (BMI) ≤18 kg/m2 or ≥40 kg/m2.

         13. Chronic kidney disease (categories С3-5 А3).

         14. Hepatic failure (Child-Pugh class C)

         15. Exacerbation or decompensation of a chronic disease that would affect the patient's
             ability to participate in the clinical trial.

         16. For smokers − intention to quit smoking in the next 4 weeks.

         17. Allergy/intolerance to any of the components of medications used in the treatment.

         18. Course intake of medicines listed in the section 'Prohibited concomitant treatment'
             for 4 weeks prior to the enrollment in the trial.

         19. Participation in other clinical trials within 3 months prior to the enrollment in this
             study.

         20. Patients who, from investigator's point of view, will fail to comply with the
             observation requirements of the trial or with the dosing regimen of the
             investigational drug.

         21. Other conditions preventing the patient from normal participation (e.g., planned
             business or other trips).

         22. Drug addiction, alcohol use in the amount over 2 units of alcohol a day, mental
             diseases.

         23. Pregnancy, breast-feeding, unwillingness to use contraception during the study.

         24. Patient is related to the research staff of the clinical investigative site who are
             directly involved in the trial or is the immediate family member of the investigator.
             The immediate family members include husband/wife, parents, children or brothers (or
             sisters), regardless of whether they are natural or adopted.

         25. Patient works for OOO &quot;NPF &quot;MATERIA MEDICA HOLDING&quot; (i.e., is the company's employee,
             temporary contract worker or appointed official responsible for carrying out the
             research or their immediate family).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD</last_name>
    <phone>+74952761571</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regional state budgetary health care institution &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Martynenko, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vladimir Martynenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional state budget health care institution &quot;City Hospital No. 5, Barnaul&quot;</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Martynenko, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Tatyana Martynenko, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NUZ &quot;Road Clinical Hospital at the station Chelyabinsk JSC&quot; RZhD &quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliya Shapovalova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yuliya Shapovalova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Institution &quot;Regional Clinical Hospital No. 4&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galina Ignatova, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Galina Ignatova, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Kazan Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr Vizel, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Aleksandr Vizel, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Kazan Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rustehm Hamitov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Rustehm Hamitov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FGBU Research Institute of Pulmonology of FMBA of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergej Avdeev, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Sergej Avdeev, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FGKU &quot;The Main Military Clinical Hospital named after academician N.N. Burdenko&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrej Zajcev, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Andrej Zajcev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pirogov Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Mikhaylusova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marina Mikhaylusova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical University named after academician I.P. Pavlov</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Abrosimov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Vladimir Abrosimov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North-western State Medical University named after I.I.Mechnikov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr Emelyanov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Aleksandr Emelyanov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Federal State Institute of Public Health 'The Nikiforov Russian Center of Emergency and Radiation Medicine'</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Pavlysh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Pavlysh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasilij Trofimov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Vasilij Trofimov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

